×
About 226,888 results

Blood Flow and Glucose Metabolism Dissociation in the Putamen Is Predictive of Levodopa Induced Dyskinesia in Parkinson's Disease Patients
https://www.frontiersin.org/articles/10.3389/fneur.2019.01217/full
Frontiers in Neurology;

Nov 20th, 2019 - The forefront treatment of Parkinson's disease (PD) is Levodopa. When patients are treated with Levodopa cerebral blood flow is increased while cerebral metabolic rate is decreased in key subcortical regions including the putamen. This phenomenon is especially pronounced in patients with Levodopa-induced dyskinesia (LID).

Liver injury in COVID-19: management and challenges
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(20)30057-1/fulltext

In December, 2019, an outbreak of a novel coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], previously 2019-nCoV) started in Wuhan, China, and has since become a global threat to human health. The number of confirmed cases of 2019 coronavirus disease (COVID-19) has reached 87 137 worldwide as of March 1, 2020, according to WHO COVID-19 situation report 41; most of the...

Herpes Zoster Ophthalmicus
https://www.aao.org/eyenet/article/herpes-zoster-ophthalmicus-pearls

Herpes zoster (HZ), or shingles, results from reactivation of latent infection with varicella- zoster virus, which also causes chicken­pox. Anyone who has had chickenpox, even in subclinical form, is at risk for developing HZ. It is estimated that the lifetime risk of HZ is 30%, and 1 mil­lion new cases are reported annually in the United States.1 An effective shingles vaccine has been approved...

Community Prevalence of SARS-CoV-2 Among Patients With Influenzalike Illnesses Presenting to a Los Angeles Medical Center in March 2020
https://jamanetwork.com/journals/jama/fullarticle/2764137
JAMA

Until recently, diagnostic testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), was only available through public health laboratories.1-3 This limited testing was prioritized for persons who had severe illness or identifiable risk factors, such as travel to an area with ongoing transmission. Thus, the incidence of c...

Selinexor/Bortezomib/Dexamethasone Triplet Improves PFS, ORR in Multiple Myeloma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200181/full/

May 28th, 2020 - Once-weekly selinexor, bortezomib, and dexamethasone (SVd) for relapsed/refractory multiple myeloma (MM) significantly improved progression-free survival (PFS) and overall response rate (ORR) when compared with twice-weekly bortezomib and dexamethasone (Vd), according to initial results from the phase III BOSTON trial (Abstract 8501).

Addition of Ublituximab to Ibrutinib Appears Safe and Effective for Patients With High-Risk Chronic Lymphocytic Leukemia
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200124/full/

May 12th, 2020 - Although chronic lymphocytic leukemia (CLL) has a relatively high 5-year survival rate (85% for people age 20 and older), effective treatments for advanced disease are still needed. Use of combination or monotherapy Bruton’s tyrosine kinase (BTK) inhibitors has shown promise for people with CLL, with the BTK inhibitor ibrutinib now considered a standard of care for patients of any age. However,...

CAR-T continues to show durable responses in indolent non-Hodgkin lymphoma
https://www.healio.com/hematology-oncology/lymphoma/news/online/{b5b2d115-7000-4df9-8743-26711c3bbde1}/car-t-continues-to-show-durable-responses-in-indolent-non-hodgkin-lymphoma

May 30th, 2020 - Axicabtagene ciloleucel induced a 93% response rate among patients with relapsed or refractory indolent non-Hodgkin lymphoma, according to interim results of the phase 2 ZUMA-5 trial presented during the ASCO20 Virtual Scientific Program.

High Rate of Responses Seen With Ide-cel in Heavily Pretreated Myeloma
https://www.targetedonc.com/view/high-rate-of-responses-seen-with-ide-cel-in-heavily-pretreated-myeloma

May 28th, 2020 - Treatment with idecabtagene vicleucel (ide-cel; bb2121) led to responses in 73% of heavily pretreated patients with relapsed or refractory multiple myeloma, and complete responses (CRs) in 33%, according to topline findings from the pivotal phase 2 KarMMA trial.

Positive Zanubrutinib Data May Spark Change for Treatment of Waldenstrom Macroglobulinemia
https://www.targetedonc.com/view/positive-zanubrutinib-data-may-spark-change-for-treatment-of-waldenstrom-macroglobulinemia

May 28th, 2020 - A higher complete response or very good partial response (CR+VGPR) rate in patients with Waldenström macroglobulinemia (WM) was achieved with Zanubrutinib (Brukinsa), and the drug demonstrated clinically meaningful safety and tolerability, according to results of the phase 3 ASPEN trial (NCT03053440).

Interim ZUMA-5 Analysis Shows Promise for Axi-Cel in Relapsed/Refractory iNHL
https://www.onclive.com/conference-coverage/asco-2020/interim-analysis-from-phase-ii-zuma5-study-shows-promise-for-axicel-in-rr-inhl

May 29th, 2020 - An interim analysis of the phase II ZUMA-5 study indicated that axicabtagene ciloleucel (axi-cel; Yescarta) demonstrated significant and durable clinical benefit, with high rates of overall response rate (ORR) and complete response (CR) observed, as well as a manageable safety profile in patients with relapsed or refractory indolent non-Hodgkin lymphoma.

Zanubrutinib Shows Efficacy, Tolerability in Waldenstrom Macroglobulinemia
https://www.onclive.com/conference-coverage/asco-2020/zanubrutinib-shows-efficacy-tolerability-in-waldenstrom-macroglobulinemia

May 28th, 2020 - Zanubrutinib (Brukinsa) was associated with a higher complete response or very good partial response (CR+VGPR) rate, as well as clinically meaningful advantages in safety and tolerability, compared with ibrutinib (Imbruvica) in patients with Waldenström macroglobulinemia (WM), according to results of the phase 3 ASPEN trial (NCT03053440).

Promising Responses Seen With Belantamab Mafodotin Triplet for R/R Multiple Myeloma
https://www.onclive.com/conference-coverage/asco-2020/promising-responses-seen-with-belantamab-mafodotin-triplet-for-rr-multiple-myeloma

May 28th, 2020 - Belantamab mafodotin in combination with bortezomib (Velcade) and dexamethasone (B-Vd) demonstrated a high rate of clinical benefit and an acceptable safety profile in patients with relapsed or refractory multiple myeloma, according to preliminary findings from a cohort of the phase 1/2 DREAMM-6 trial.

Updated CARTITUDE-1 Results Continue to Demonstrate Safety, Durable Responses for JNJ-4528 in R/R Multiple Myeloma
https://www.onclive.com/conference-coverage/asco-2020/updated-cartitude1-results-continue-to-demonstrate-safety-durable-responses-for-jnj4528-in-rr-multiple-myeloma

May 28th, 2020 - The chimeric antigen receptor (CAR) T-cell therapy, JNJ-4528, continued to demonstrate deep and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma, according to updated findings from the phase 1b/2 CARTITUDE-1 (NCT03548207) trial. Lead author Jesus G. Berdeja, MD, reported that the overall response rate (ORR) was 100%, with a stringent complete response (...

Selinexor Triplet Improves Response, Reduces Neuropathy in Relapsed/Refractory Multiple Myeloma
https://www.onclive.com/conference-coverage/asco-2020/adding-selinexor-to-bortezomib-and-dexamethasone-improves-response-and-reduces-neuropathy-in-patients-with-multiple-myeloma

May 28th, 2020 - When added to bortezomib (Velcade) and dexamethasone in patients with multiple myeloma, selinexor (Xpovio), an inhibitor of XPO1-mediated nuclear export, improves progression-free survival (PFS) and overall response rate (ORR) and reduces the incidence of peripheral neuropathy.

Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort
https://www.nature.com/articles/s41531-018-0069-x
NPJ Parkinson's Disease;

Levodopa-induced dyskinesias (LID) negatively impact on the quality of life of patients with Parkinson’s disease (PD). We assessed the risk factors for LID in a cohort of de-novo PD patients enrolled in the Parkinson’s Progression Markers Initiative (PPMI). This retrospective cohort study included all PD patients enrolled in the PPMI cohort. Main outcome was the incidence rate of dyskinesia, de...

Mathematical model of infection kinetics and its analysis for COVID-19, SARS and MERS
https://www.sciencedirect.com/science/article/pii/S1567134820301374
Infection, Genetics and Evolution;

The purpose of this paper is to reveal the spread rules of the three pneumonia: COVID-19, SARS and MERS. We compare the new spread characteristics of COVID-19 with those of SARS and MERS. By considering the growth rate and inhibition constant of infectious diseases, their propagation growth model is established. The parameters of the three coronavirus transmission growth models are obtained by ...

Household Transmission of SARS-CoV-2 in the United States
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1166/5893024
Clinical Infectious Diseases; Lewis, NM. et. al.

Although many viral respiratory illnesses are transmitted within households, the evidence base for SARS-CoV-2 is nascent. We sought to characterize SARS-CoV-2 transmission within US households and estimate the household secondary infection rate (SIR) to inform strategies to reduce transmission.

Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/lymphoma/hp/child-nhl-treatment-pdq?cid=eb_govdel

Dramatic improvements in survival have been achieved for children and adolescents with cancer.[1] Between 1975 and 2010, childhood cancer mortality decreased by more than 50%.[1] For NHL, the 5-year survival rate increased over the same time period, from 45% to 87% in children younger than 15 years and from 48% to 82% for adolescents aged 15 to 19 years.[1]

Pancreatic Cancer: Screening - Draft Recommendation Statement
https://www.uspreventiveservicestaskforce.org/Page/Document/draft-recommendation-statement/pancreatic-cancer-screening1

Feb 4th, 2019 - The USPSTF recommends against screening for pancreatic cancer in asymptomatic adults. Pancreatic ductal adenocarcinoma (referred to hereafter as pancreatic cancer) is an uncommon cancer with an age-adjusted annual incidence of 12.6 cases per 100,000 person-years. However, the death rate is 10.9 deaths per 100,000 person-years because the prognosis of pancreatic cancer is poor. Although its inci...

Rising cancer incidence in younger adults: is obesity to blame?
https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(19)30017-9/fulltext
Marinac,C.,et al

Feb 2nd, 2019 - Although cancer has historically been considered a disease of aging, a reported sharp rise in colorectal cancer incidence among adults aged 54 years and younger beginning in the mid-1980s for the colon and mid-1970s for the rectum has motivated researchers to examine risk factors for early onset disease. In The Lancet Public Health, Hyuna Sung and colleagues3 report a rigorous and extensive ana...